RSS

PARP Inhibitors

The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the marketing authorisation of Lynparza (olaparib) tablets for patients with platinum-sensitive relapsed ovarian, fallopian tube, or primary perito more

News

The FDA has given the green light to an expansion of use of olaparib tablets (Lynparza) to now include the treatment of patients with certain types of breast cancer that have metastasized and whose tumours have a specific inherited genetic mutation. more

News

Biopharmaceutical company, Tesaro, has revealed that the European Commission has approved its monotherapy for the maintenance treatment of women with recurrent ovarian cancer. more

News

The US Food and Drug Administration (FDA) has accepted and granted priority review of a supplemental new drug application (sNDA) for Lynparza to be used in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer. more

News

A study, from an international team of researchers, may offer hope to patients with prostate cancer as it shows that a combination therapy could potentially reduce the recurrence rate of the disease. more

News

One in five women with breast cancer could benefit from existing treatments previously thought not to be effective. more

News